BSX vs CLMT · P/E 20, rev $16.75B vs rev $4.19B
Boston Scientific Corp (BSX) versus Calumet Specialty Products Partners (CLMT) — a side-by-side from cached financials, not a winner call.
Boston Scientific Corp (BSX) is a medical devices company listed on US.
Calumet Specialty Products Partners (CLMT) is a specialty chemicals company listed on NASDAQ.
Latest reported BSX revenue for 2024-12-31 was $16.75B. Net income was $1.85B. Revenue was up 17.6% from 2023-12-31 to 2024-12-31. BSX currently screens at market cap $71.81B and trailing P/E 20.2.
Latest reported CLMT revenue for 2024-12-31 was $4.19B. Net income was -$222.0M. Revenue was up 0.2% from 2023-12-31 to 2024-12-31. CLMT currently screens at market cap $2.89B.
BSX currently screens at market cap $71.81B and trailing P/E 20.2. CLMT currently screens at market cap $2.89B.
Not investment advice. Open the BSX and CLMT stock pages for the full models.
Not investment advice.